NeuBase Therapeutics, Inc. NBSE
Set alert
0.38 +0.38 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 1.42M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -0.03
- Beta
- 0.94
- Short ratio
- 0.24
- Inst. own
- 11.87%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 26, 2024
- 50-d avg
- 0.472587
- 200-d avg
- 0.722122
- 1y target
- 0.00
3M chart
Signals (8)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Apr 18, 2024 | 2 years ago |
| RSI: Oversold | Apr 16, 2024 | 2 years ago |
| SMA: Bearish | Mar 26, 2024 | 2 years ago |
| SMA: Bearish | Mar 26, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 26, 2024 | 2 years ago |
| RSI: Oversold | Mar 26, 2024 | 2 years ago |
| RSI: Overbought | Mar 18, 2024 | 2 years ago |
| RSI: Overbought | Feb 26, 2024 | 2 years ago |
Key statistics
- Market cap
- 1.42M
- Enterprise value
- -5.83M
- Trailing P/E
- 0.00
- Forward P/E
- -0.03
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.15
- EPS (TTM)
- -18.60
- Beta
- 0.94
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -15.18M
- Total cash
- 12.57M
- Total debt
- 5.34M
- Return on equity
- -93.46%
- Shares outstanding
- 3.75M
- Short % of float
- 0.44%
- 50-day average
- 0.472587
- 200-day average
- 0.722122
Analyst view
Consensus: hold
Hold
Price target (mean) 0.00
Next earnings
Dec 26, 2024
Expected Dec 26, 2024. Consensus EPS estimate 0.00.
Financials — quick view
NBSE Revenue — quarterly 0
NBSE Net income — quarterly -1.82M
NBSE EPS — quarterly -0.66
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 26, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Sep 30, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jul 4, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -1.82 | -0.95 | +0.87 | +47.80% |
| Aug 14, 2023 | Jun 1, 2023 | -1.80 | -1.26 | +0.54 | +30.00% |
About NeuBase Therapeutics, Inc.
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- neubasetherapeutics.com
News
- NeuBase Therapeutics Announces Receipt of Notice from Nasdaq
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- Cheap Penny Stocks To Buy Now? 3 For Your Watch List
- NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder
- NeuBase (NBSE) Surges 107% on New Shareholder Acquiring Stake
- Why Is NeuBase Therapeutics (NBSE) Stock Down 27% Today?
- SYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASE
Your note
Sign in to keep a note on NBSE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALMENOFF JUNE SHERIE | Director | Purchase | Feb 5, 2015 | 16,900 |
| BACKENROTH SAMUEL | Chief Financial Officer | Purchase | Apr 29, 2020 | 11,630 |
| BRANNING TODD P | Chief Financial Officer | Stock Award(Grant) | Mar 15, 2023 | 84,200 |
| GOLDSTEIN DOV A | Director | Purchase | Jun 17, 2021 | 30,000 |
| HIRSCHMAN ORIN | Director | Purchase | Apr 9, 2017 | 0 |
| MANN WILLIAM ROLAND | Chief Operating Officer | Purchase | Mar 29, 2022 | 11,200 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 7.03% | 166,174 | 310.75K | Jun 29, 2023 |
| Greenlight Capital, Inc. | 5.77% | 136,350 | 254.97K | Jun 29, 2023 |
| Point72 Asset Management, L.P. | 2.65% | 62,500 | 116.88K | Jun 29, 2023 |
| Decheng Capital Management III (Cayman), LLC | 2.12% | 50,000 | 93.50K | Jun 29, 2023 |
| Carnegie Mellon University | 1.99% | 46,970 | 87.83K | Jun 29, 2023 |
| Kestra Advisory Services, LLC | 1.08% | 25,483 | 47.65K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.80% | 18,981 | 35.49K | Jun 29, 2023 |
| Jacob Discovery Fd | 0.66% | 15,655 | 15.19K | Aug 30, 2023 |
| Fidelity Extended Market Index Fund | 0.30% | 7,081 | 25.22K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.06% | 1,425 | 5.08K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.06% | 1,359 | 4.84K | May 30, 2023 |
| Schwab Capital Trust-Total Stock Market Index Fund | 0.06% | 1,485 | 2.06K | Jul 30, 2023 |